Literature DB >> 21793816

Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening.

Evelyn M van der Plas1, Xandra W van den Tweel, Ronald B Geskus, Harriët Heijboer, Bart J Biemond, Marjolein Peters, Karin Fijnvandraat.   

Abstract

This study analyzed the mortality and causes of death in sickle cell disease patients in the Netherlands, to provide a baseline for monitoring the effect of the recently introduced neonatal screening programme and to indicate areas of improvement in the care for these patients. All children (<18 years) diagnosed with sickle cell disease in a tertiary hospital from 1985 to 2007 were included. Vital status was determined up to March 2008. A total of 298 children were included: 189 (63%) patients had HbSS, 17 (6%) HbSβ(0) thalassaemia, 72 (24%) HbSC and 20 (7%) HbSβ(+) thalassaemia. Twelve patients (4%) died during a total follow-up of 3896 patient years. All known deaths were sickle cell disease-related. Meningitis/sepsis (n=4; 33%), stroke (n=3; 25%) and death during a visit to the country of origin (n=3; 25%) were the most common causes of death. The overall mortality rate was 0·27 deaths/100 patient years [95% confidence interval (CI): 0·15-0·43]. The estimated survival at the age of 18 years was 97·3% (95% CI: 95-99%). This report confirms that the burden of mortality in sickle cell disease is increasingly shifting to adults. It is recommended that compliance to antibiotic prophylaxis, thorough counselling and support for patients travelling abroad and specialized peri-operative care should receive continuous attention.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21793816     DOI: 10.1111/j.1365-2141.2011.08806.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel.

Authors:  Emanuele Angelucci; Susanne Matthes-Martin; Donatella Baronciani; Françoise Bernaudin; Sonia Bonanomi; Maria Domenica Cappellini; Jean-Hugues Dalle; Paolo Di Bartolomeo; Cristina Díaz de Heredia; Roswitha Dickerhoff; Claudio Giardini; Eliane Gluckman; Ayad Achmed Hussein; Naynesh Kamani; Milen Minkov; Franco Locatelli; Vanderson Rocha; Petr Sedlacek; Frans Smiers; Isabelle Thuret; Isaac Yaniv; Marina Cavazzana; Christina Peters
Journal:  Haematologica       Date:  2014-05       Impact factor: 9.941

Review 2.  Prospects for primary stroke prevention in children with sickle cell anaemia.

Authors:  Lori C Jordan; James F Casella; Michael R DeBaun
Journal:  Br J Haematol       Date:  2012-01-09       Impact factor: 6.998

Review 3.  Hydroxyurea (hydroxycarbamide) for sickle cell disease.

Authors:  Angela E Rankine-Mullings; Sarah J Nevitt
Journal:  Cochrane Database Syst Rev       Date:  2022-09-01

4.  Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study.

Authors:  Mehdi Nouraie; Deepika S Darbari; Sohail Rana; Caterina P Minniti; Oswaldo L Castro; Lori Luchtman-Jones; Craig Sable; Niti Dham; Gregory J Kato; Mark T Gladwin; Gregory Ensing; Manuel Arteta; Andrew Campbell; James G Taylor; Sergei Nekhai; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2020-04-21       Impact factor: 10.047

Review 5.  Hydroxyurea (hydroxycarbamide) for sickle cell disease.

Authors:  Sarah J Nevitt; Ashley P Jones; Jo Howard
Journal:  Cochrane Database Syst Rev       Date:  2017-04-20

6.  Survival and mortality among users and non-users of hydroxyurea with sickle cell disease.

Authors:  Olinda Maria Rodrigues de Araujo; Maria Lúcia Ivo; Marcos Antonio Ferreira Júnior; Elenir Rose Jardim Cury Pontes; Ieda Maria Gonçalves Pacce Bispo; Eveny Cristine Luna de Oliveira
Journal:  Rev Lat Am Enfermagem       Date:  2015 Jan-Feb

7.  Mortality by sickle cell disease in Brazil.

Authors:  Giovanna Abadia Oliveira Arduini; Letícia Pinto Rodrigues; Alessandra Bernadete Trovó de Marqui
Journal:  Rev Bras Hematol Hemoter       Date:  2016-10-21

8.  Evaluation of newborn sickle cell screening programme in England: 2010-2016.

Authors:  Allison Streetly; Rupa Sisodia; Moira Dick; Radoslav Latinovic; Kirsty Hounsell; Elizabeth Dormandy
Journal:  Arch Dis Child       Date:  2017-11-05       Impact factor: 3.791

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.